Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy to Prevent Colorectal Peritoneal Metastases (ProphyPIPAC)

Peritoneal Metastases From Colorectal Cancer Clinical Trial

— ProphyPIPAC  

Official title:

Pilot Study of Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for the Prevention of Peritoneal Metastases After Curative-intent Surgery for High-risk Colorectal Cancer.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06091683
• Other study ID #: INT 0068/20
• Secondary ID: 2020-000604-11BR
• Status: Recruiting
• Phase: N/A
• Start date: April 30, 2021
• Est. completion date: December 31, 2025

Study information

• Verified date: October 2023
• Source: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
• Contact: Dario Baratti, MD
• Phone: +390223901
• Email: dario.baratti[@]istitutotumori.mi.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this clinical trial is to demonstrate the feasibility and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the prevention of peritoneal metastases after curative-intent surgery for high-risk colorectal cancer.

Description:

This single-arm, single-center, open-label trial enrolls patients after curative-intent surgery for colon adenocarcinoma (proximal to peritoneal reflection), intestinal or mucinous histological type, associated with the following clinical-pathological risk factors for the development of peritoneal metastases: a) stage pT4a, N0-2b, M0 of the Tumor Node Metastasis classification; b) stage pT4b, N0-2b, M0; and c) primary perforated tumor (any T, any N, M0). Eligible patients who will give informed consent undergo laparoscopic pressurized intraperitoneal aerosol chemotherapy (PIPAC) 4 to 8 weeks after primary surgery, followed by adjuvant systemic chemotherapy according to according to current guidelines. After the procedure, patients will be followed-up to assess occurrence of adverse events,survival, peritoneal and systemic disease relapse, and quality of life.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Histopathological diagnosis of intestinal type, mucinous or signet ring cell adenocarcinoma of the colon (with upper limit of the tumor above peritoneal reflection);

2. curative (microscopically complete) surgery performed by laparotomy or laparoscopy;

3. presence of at least one of the following risk factors for the development of metachronous peritoneal metastases:

• perforated primary tumor (any T, N0-2b, M0);

• primary tumor infiltrating the visceral peritoneum (pT4a, N0-2b, M0), or directly invading adjacent organs (pT4b, N0-2b, M0);

4. age > 18;

5. performance status 2 according to the World Health Organization score;

6. willingness to start adjuvant systemic chemotherapy and post-operative follow-up;

7. Signing of informed consent.

Exclusion Criteria:

1. active sepsis;

2. cardiac function impairment (history of previous heart failure or 40% ejection fraction);

3. renal impairment (serum creatinine >1.5 normal value or creatinine clearance 60 ml/min);

4. liver function impairment (aspartate aminotransferase, alanine aminotransferase, bilirubin > 1.5 normal value);

5. bone marrow function impairment (leukocytes 4000 / mm3, neutrophils 1500 /mm3, platelets 80000/mm3);

6. lung function impairment (diagnosis of severe chronic obstructive pulmonary disease or 50% forced expiratory volume at one second or 40% diffusion capacity of lung for carbon monoxide adjusted for age);

7. extra-abdominal and/or hepatic metastases at the Computed Tomography scan of the chest, abdomen and pelvis with intravenous contrast;

8. severe complications (grade 3-4) after primary cancer surgery;

9. haemorrhagic diathesis or coagulopathy;

10. pregnancy or lactation in progress;

11. psychiatric or neurological conditions such as to preclude protocol procedures; 12) contraindications to laparoscopy; 13) known hypersensitivity to oxaliplatin or other platinum containing compounds and/or to any of their excipients; 14) history of previous malignancies treated in the last three years, excluding cutaneous spinocellular carcinoma and/or basocellular carcinoma; 15) prior pre-operative radio-chemotherapy..

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Neoplasm Metastasis
• Peritoneal Metastases From Colorectal Cancer

Intervention

Procedure:
• Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Laparoscopic exploration of the abdominal cavity with dissection of adhesions and biopsies of suspect findings (if needed). PIPAC will be administered with oxaliplatin (92 mg/m2 body surface area in 150 ml dextrose solution) for 30 minutes under the following spraying conditions: cytostatic application at a rate of 30 ml/min, pressure of 1380 kilo-pascal over 30 minutes, and temperature of 22°C. One hour before the beginning of PIPAC, intravenous infusion of 5-fluorouracil (400 mg/m2) and folinic acid (20mg/m2) will be initiated. Standard protectionist procedures will be adopted to avoid contamination of operators and the environment with nebulized chemotherapy.

Locations

Country	Name	City	State
Italy	Fondazione IRCCS Istituto Nazionale dei Tumori	Milano

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC)	The adjuvant PIPAC performed in an early setting after primary surgery will be considered feasible if: the laparoscopic procedure can be completed in 9 patients; the postoperative stay will be three days or shorter in =6 patients; the post-operative adjuvant s-CT will begin within 12 weeks of primary surgery in = 9 patients.	12 weeks
Primary	Safety of adjuvant pressurized intraperitoneal aerosol chemotherapy (PIPAC)	The adjuvant PIPAC will be considered a well tolerated procedure if: a maximum of one serious treatment-related complication will occur; a maximum of one laparotomy conversion will occur; a maximum of one hospital readmission will occur within 30 days.	30 days
Secondary	Overall survival	Overall survival will be measured from the date of primary surgery to the date of death for any cause or, for patients still alive at the date of the last available follow-up.	60 months
Secondary	Disease-free survival	Disease-free survival will be measured from the date of primary surgery to the date of peritoneal metastasis diagnosis, systemic metastases or death.	60 months
Secondary	Peritoneal disease-free survival	Peritoneal disease-free survival will be measured from the date of primary surgery to the date of peritoneal metastasis diagnosis,	60 months